TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Epidemiology of HIV/AIDS by Key Countries 4.2. Overview of Pipeline Analysis 4.3. Regulatory Scenario by Key Countries 4.4. Pricing Analysis 4.5. Key Strategies Employed by Market Leaders in Various Regions 4.6. Overview of New Product Launches 5. Global HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis, Insights and Forecast – By Drug Class 5.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 5.2.2. Integrase Inhibitors 5.2.3. Combination HIV Medicines 5.2.4. Others 5.3. Market Analysis, Insights and Forecast – By Distribution Channel 5.3.1. Hospital Pharmacies 5.3.2. Retail Pharmacies 5.3.3. Online Pharmacies 5.3.4. Others 5.4. Market Analysis, Insights and Forecast – By Region 5.4.1. North America 5.4.2. Europe 5.4.3. Asia Pacific 5.4.4. Rest of World 6. North America HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By Drug Class 6.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 6.2.2. Integrase Inhibitors 6.2.3. Combination HIV Medicines 6.2.4. Others 6.3. Market Analysis – By Distribution Channel 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Online Pharmacies 6.3.4. Others 6.4. Market Analysis – By Country 6.4.1. U.S. 6.4.2. Canada 7. Europe HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By Drug Class 7.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 7.2.2. Integrase Inhibitors 7.2.3. Combination HIV Medicines 7.2.4. Others 7.3. Market Analysis – By Distribution Channel 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.3.4. Others 7.4. Market Analysis – By Country/ Sub-Region 7.4.1. U.K. 7.4.2. Germany 7.4.3. France 7.4.4. Spain 7.4.5. Italy 7.4.6. Scandinavia 7.4.7. Rest of Europe 8. Asia Pacific HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By Drug Class 8.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 8.2.2. Integrase Inhibitors 8.2.3. Combination HIV Medicines 8.2.4. Others 8.3. Market Analysis – By Distribution Channel 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.3.4. Others 8.4. Market Analysis – By Country/ Sub-Region 8.4.1. Japan 8.4.2. China 8.4.3. India 8.4.4. Australia 8.4.5. Southeast Asia 8.4.6. Rest of Asia Pacific 9. Rest of World HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By Drug Class 9.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 9.2.2. Integrase Inhibitors 9.2.3. Combination HIV Medicines 9.2.4. Others 9.3. Market Analysis – By Distribution Channel 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.3.4. Others 10. Competitive Analysis 10.1. Key Industry Developments 10.2. Global Market Share Analysis (2017) 10.3. Competition Dashboard 10.4. Comparative Analysis – Major Players 10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability)) 10.5.1. Gilead Sciences, Inc. 10.5.2. ViiV Healthcare 10.5.3. GlaxoSmithKline plc 10.5.4. Merck Sharp & Dohme Corp. 10.5.5. Bristol-Myers Squibb Company 10.5.6. Janssen Pharmaceuticals, Inc. 10.5.7. F. Hoffmann-La Roche Ltd 10.5.8. Theratechnologies Inc. 10.5.9. Mylan Pharmaceuticals Inc. 10.5.10. AbbVie Inc. 11. Strategic Recommendations

ViiV Healthcare Gilead Sciences, Inc. Merck Sharp & Dohme Corp. Bristol-Myers Squibb Company Janssen Pharmaceuticals, Inc. Theratechnologies Inc. Mylan Pharmaceuticals Inc. Genentech, Inc. AbbVie Inc.